Fraser-Andrews E A, Mitchell T, Ferreira S, Seed P T, Russell-Jones R, Calonje E, Whittaker S J
Department of Dermatopathology, St John's Institute of Dermatology, St Thomas' Hospital, London SE1 7EH, UK.
Br J Dermatol. 2006 Oct;155(4):756-62. doi: 10.1111/j.1365-2133.2006.07428.x.
Histological evidence of lymph node involvement is associated with a poor prognosis in patients with cutaneous T-cell lymphoma (CTCL).
To determine whether T-cell receptor (TCR) gene analysis is of prognostic relevance in CTCL.
TCR gene analysis was performed on lymph node specimens from 60 patients with mycosis fungoides (MF) and Sézary syndrome (SS) using a highly sensitive polymerase chain reaction (PCR)/single-strand conformational polymorphism analysis and results were correlated with skin, overall clinical and histological lymph node stages.
The frequency with which a T-cell clone was detected in lymph node samples from patients with MF increased with skin stage, overall clinical stage and with the degree of histological involvement: six of 19 patients with uninvolved lymph nodes or limited histological involvement (LN0-2) and 13 of 14 patients with advanced histological involvement (LN3-4) had a detectable T-cell clone. In SS, 22 of 27 patients had a detectable lymph node T-cell clone. The clonal patients had a poorer prognosis than nonclonal patients (median survival from biopsy of > 72 months vs. 16 months for MF and 41.5 vs. 16.5 months for SS). Regression analysis confirmed that TCR gene analysis identifies a group of MF patients with a worse prognosis (P = 0.013). However, the molecular lymph node stage did not provide independent prognostic information in this cohort of patients in multivariate analysis.
Molecular staging in MF and SS using a PCR-based method for TCR gene analysis provides additional information to histological examination. Specifically, this study identified a group of MF patients with early lymph node involvement with a poorer prognosis. However, a larger prospective study of patients with MF and early histological lymph node involvement is required to confirm whether molecular staging of lymph nodes provides independent prognostic information in a multivariate model.
皮肤T细胞淋巴瘤(CTCL)患者的淋巴结受累组织学证据与预后不良相关。
确定T细胞受体(TCR)基因分析在CTCL中是否具有预后相关性。
使用高灵敏度聚合酶链反应(PCR)/单链构象多态性分析对60例蕈样肉芽肿(MF)和 Sézary 综合征(SS)患者的淋巴结标本进行TCR基因分析,并将结果与皮肤、总体临床和组织学淋巴结分期相关联。
MF患者淋巴结样本中检测到T细胞克隆的频率随皮肤分期、总体临床分期和组织学受累程度增加:19例无淋巴结受累或组织学受累有限(LN0 - 2)的患者中有6例,14例组织学受累晚期(LN3 - 4)的患者中有13例检测到可检测的T细胞克隆。在SS中,27例患者中有22例检测到淋巴结T细胞克隆。克隆患者的预后比非克隆患者差(MF患者活检后的中位生存期分别为>72个月和16个月,SS患者分别为41.5个月和16.5个月)。回归分析证实,TCR基因分析可识别出一组预后较差的MF患者(P = 0.013)。然而,在多变量分析中,分子淋巴结分期并未为该队列患者提供独立的预后信息。
使用基于PCR的方法进行TCR基因分析对MF和SS进行分子分期可为组织学检查提供额外信息。具体而言,本研究确定了一组早期淋巴结受累且预后较差的MF患者。然而,需要对MF和早期组织学淋巴结受累患者进行更大规模的前瞻性研究,以确认淋巴结分子分期在多变量模型中是否提供独立的预后信息。